PMID- 33112113
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1233-9687 (Print)
IS  - 1233-9687 (Linking)
VI  - 71
IP  - 3
DP  - 2020
TI  - The value of BAP1 immunocytochemistry and CDKN2A fluorescence in situ 
      hybridization in diagnosis of serous effusion malignant mesothelioma and an 
      analysis of the association between degree of cell atypia and the results of two 
      auxiliary methods.
PG  - 229-235
LID - 42023 [pii]
LID - 10.5114/pjp.2020.99789 [doi]
AB  - Malignant mesothelioma (MM) is a rare, highly aggressive tumor. The first symptom 
      of MM is mostly serous effusion, and cytology can be used in diagnosis based on 
      effusion, providing patients with an earlier diagnosis and treatment opportunity. 
      A total of 67 specimens were embedded into cell blocks, and BAP1 
      immunocytochemistry (ICC) was performed. CDKN2A fluorescence in situ 
      hybridization (FISH) was performed in 45 cases. The sensitivity, specificity and 
      the association between the degree of cell atypia and the results of two 
      auxiliary methods were analyzed. BAP1 ICC showed nonexpression in 13 of 24 cases 
      of MM and 0 of 21 cases of benign mesothelial proliferation (BMP). The 
      sensitivity was 54.2% (13/24), and the specificity was 100% (21/21). In addition, 
      22 metastatic adenocarcinoma (MA) cases all showed BAP1 expression. MM with BAP1 
      expression had more obvious cell atypia. CDKN2A deletion was found in 12 of 24 MM 
      cases and 0 of 21 BMP cases. The sensitivity was 50% (12/24), and the specificity 
      was 100% (21/21). BAP1 ICC and CDKN2A FISH are useful methods to differentiate MM 
      from BMP. The cell atypia of MM with BAP1 expression was more obvious than MM 
      with BAP1 nonexpression.
FAU - Ren, Wenhao
AU  - Ren W
AD  - Department of Pathology and Resident Training Base, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Zhao, Lin-Lin
AU  - Zhao LL
AD  - Department of Pathology and Resident Training Base, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Guo, Lei
AU  - Guo L
AD  - Department of Pathology and Resident Training Base, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Lu, Ning
AU  - Lu N
AD  - Department of Pathology and Resident Training Base, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Cao, Jian
AU  - Cao J
AD  - Department of Pathology and Resident Training Base, National Cancer 
      Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
AD  - Department of Pathology, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Shenzhen, China.
LA  - eng
PT  - Journal Article
PL  - Poland
TA  - Pol J Pathol
JT  - Polish journal of pathology : official journal of the Polish Society of 
      Pathologists
JID - 9437432
RN  - 0 (BAP1 protein, human)
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Cyclin-Dependent Kinase Inhibitor p16
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - *Mesothelioma, Malignant/diagnosis
MH  - Tumor Suppressor Proteins
MH  - Ubiquitin Thiolesterase
OTO - NOTNLM
OT  - BAP1
OT  - CDKN2A
OT  - fluorescence in situ hybridization
OT  - immunocytochemistry
OT  - malignant mesothelioma
EDAT- 2020/10/29 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/10/28 10:32
PHST- 2020/10/28 10:32 [entrez]
PHST- 2020/10/29 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
AID - 42023 [pii]
AID - 10.5114/pjp.2020.99789 [doi]
PST - ppublish
SO  - Pol J Pathol. 2020;71(3):229-235. doi: 10.5114/pjp.2020.99789.